STAGE IIIA2 OVARIAN CANCER AJCC V8
Clinical trials for STAGE IIIA2 OVARIAN CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIA2 OVARIAN CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IIIA2 OVARIAN CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise in shrinking ovarian tumors before surgery
Disease control OngoingThis early-phase trial tested the drug olaparib in 15 people with newly diagnosed BRCA-mutant ovarian, fallopian tube, or peritoneal cancer before they had surgery. The goal was to see if taking olaparib for two cycles could shrink tumors or stop them from growing. Olaparib works…
Matched conditions: STAGE IIIA2 OVARIAN CANCER AJCC V8
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 10, 2026 13:25 UTC
-
Can we predict who will get nerve damage from chemo?
Knowledge-focused OngoingThis study aims to find out why some cancer patients develop nerve damage (tingling or numbness in hands and feet) from taxane chemotherapy. Researchers will track over 1,300 people with breast, lung, or ovarian cancer to see how age, gender, and other factors affect their risk. …
Matched conditions: STAGE IIIA2 OVARIAN CANCER AJCC V8
Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated Jun 03, 2026 12:04 UTC